EDIT - Editas Medicine Inc Stock Price, Fair Value and News

$1.28+0.01 (+0.79%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

EDIT Price Action

Last 7 days

15.3%

Last 30 days

-3.0%

Last 90 days

4.9%

Trailing 12 Months

-77.2%

EDIT RSI Chart

EDIT Valuation

Market Cap

106.2M

Price/Earnings (Trailing)

-0.45

Price/Sales (Trailing)

3.29

Price/Free Cashflow

-0.48

EDIT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

EDIT Fundamentals

EDIT Revenue

Revenue (TTM)

32.3M

Rev. Growth (Yr)

-49.03%

Rev. Growth (Qtr)

96.7%

EDIT Earnings

Earnings (TTM)

-237.1M

Earnings Growth (Yr)

-140.52%

Earnings Growth (Qtr)

26.95%

EDIT Profitability

Return on Equity

-176.57%

Return on Assets

-69.41%

Free Cashflow Yield

-206.3%

EDIT Investor Care

Shares Dilution (1Y)

1.42%

Diluted EPS (TTM)

-2.88

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	66.7M	55.2M	43.8M	32.3M
2023	22.8M	19.3M	24.6M	78.1M
2022	25.8M	31.8M	25.6M	19.7M
2021	91.5M	81.1M	24.5M	25.5M
2020	24.2M	32.6M	91.6M	90.7M
2019	30.1M	25.0M	14.4M	20.5M
2018	17.0M	21.2M	29.5M	31.9M
2017	5.9M	5.6M	11.0M	13.7M
2016	2.4M	5.7M	5.9M	6.1M
2015	0	0	0	1.6M

Get all data in R, Python etc through our Historical Stock Data APIs

About Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis 10; autosomal dominant retinitis pigmentosa; and EDIT-301, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

CEO	Dr. Gilmore O'Neill
WEBSITE	editasmedicine.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	226

Editas Medicine Inc Frequently Asked Questions

What is the ticker symbol for Editas Medicine Inc? What does EDIT stand for in stocks?

EDIT is the stock ticker symbol of Editas Medicine Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Editas Medicine Inc (EDIT)?

As of Thu Apr 17 2025, market cap of Editas Medicine Inc is 106.21 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EDIT stock?

You can check EDIT's fair value in chart for subscribers.

Is Editas Medicine Inc a good stock to buy?

The fair value guage provides a quick view whether EDIT is over valued or under valued. Whether Editas Medicine Inc is cheap or expensive depends on the assumptions which impact Editas Medicine Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EDIT.

What is Editas Medicine Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 17 2025, EDIT's PE ratio (Price to Earnings) is -0.45 and Price to Sales (PS) ratio is 3.29. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EDIT PE ratio will change depending on the future growth rate expectations of investors.